circRNA basic information
circBase ID: hsa_circ_0000605
Name: hsa_circ_SLTM
Synonym: circSLTM
Host Gene: SLTM
Genomic location(hg19): chr15:59204761-59209198:-
Genomic location(hg38): chr15:58912562-58916999:-
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0005178
MONDO name: osteoarthritis
Disease details: osteoarthritis
Disease DO ID:
 8398
Disease MeSH ID:
 D010003
Disease NCIt ID:
 C3293
Disease ICD11 ID:
 558562409
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

Human cartilage tissues; OA cartilage tissues; Normal human articular cartilage samples; mouse articular cartilage tissues; knee joint tissues
Cell lines:

CHON-001
In vivo animal model:

other disease animal model
circRNA-disease information
Expression pattern:
UP
Associated gene: VAPB, Ago2, p65, IkappaBalpha, IL-1beta, IL-6, TNF-alpha, MMP13, ADAMTS5, collagen II
Associated microRNA: miR-515-5p
Biological function: circSLTM promotes OA-like chondrocyte injury by reducing proliferation and enhancing apoptosis, inflammatory factor expression, extracellular matrix degradation, and cartilage damage; circSLTM knockdown enhances proliferation, reduces apoptosis and inflammatory factors, restores ECM protein changes, and attenuates cartilage defects in vivo.
Molecular mechanism: circSLTM acts as a ceRNA that binds miR-515-5p and positively regulates VAPB expression, thereby contributing to LPS-induced chondrocyte dysfunction and NF-kappaB signaling activation.
Biological pathway or process:

ceRNA regulation (other); NF-kappaB (promotes); apoptosis (promotes); inflammation (promotes); proliferation (inhibits); other pathway/process (promotes)
Detected method:
Q
Validation methods:

RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry)
Clinical significance:

High circSLTM expression was significantly associated with extended disease duration in OA patients; circSLTM may be a potential therapeutic target for OA treatment.
Description:

circSLTM/hsa_circ_0000605 is up-regulated in OA cartilage tissues and LPS-treated human chondrocytes. It promotes OA progression by acting as a ceRNA for miR-515-5p to increase VAPB expression and activate NF-kappaB signaling, leading to inflammation, apoptosis, ECM degradation, and reduced chondrocyte proliferation. Knockdown of circSLTM protects chondrocytes in vitro and alleviates cartilage damage in an ACLT-induced OA mouse model.
Confidence score:

0.8571
Other information
Title:

circSLTM knockdown attenuates chondrocyte inflammation, apoptosis and ECM degradation in osteoarthritis by regulating the miR-515-5p/VAPB axis.

Journal: International immunopharmacology
Published: 2024
PubMed ID: 38981227
Study type:

combined biological and clinical study
Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request; Supplementary data to this article can be found online at https://doi.org/10.1016/j.intimp.2024.112435.
Code availability: -